All Updates

All Updates

icon
Filter
M&A
Geographic expansion
Numinus Wellness completes acquisition of Novamind; enters US market
Psychedelic Medicine
Jun 10, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jun 10, 2022

Numinus Wellness completes acquisition of Novamind; enters US market

M&A
Geographic expansion

  • Canadian psychedelic company Numinus Wellness has completed its previously announced acquisition of psychedelic wellness company Novamind for CAD 26.2 million (USD 20.7 million). 

  • In connection with the acquisition, Numinus has issued around 43.5 million common shares to Novamind shareholders and restricted share unit (RSU) holders. Novamind’s warrant holders, with 19 million outstanding warrants, will be eligible to acquire up to 16 million shares on a ratio of 0.84:1. 

  • Post-acquisition, Numinus will operate 13 psychedelic-assisted wellness clinics including eight acquired from Novamind (which will be rebranded to Numinus later this year), four clinical research facilities, and a dedicated psychedelics research laboratory. Numinus also appointed Novamind employees Reid Robison and Paul Thielking as its chief clinical officer and chief science officer, respectively. 

  • Numinus intends to leverage Novamind’s geographical presence and investor base in the US to expand its market and attract investments from US corporations. It also indicated the potential of the combined entity to generate revenues of CAD 11.9 million (~USD 9.2 million) (on a proforma basis) annually.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.